| SEC For | m 4 FORM | Λ | | τΔΤΙ | =5 5 | FCUR | ITIF | S AND | EXCH/ | | | SION | | | | |
|-----------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------|----------------------------------------------------------------|--------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------|--------|----------------------------------------------------------------|--------------------|------------------------------------------------------------|-------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------|--------------|--------------------------------------------------------------------------|--------------------------------------------------------------------|
| | | | UNITED STATES SECURITIES AND EXCHANGE COMMISSIO Washington, D.C. 20549 | | | | | | | | | | | OMB APPROVAL | | |
| Check Section obligat Instruc | STATE | STATEMENT OF CHANGES IN BENEFICIAL OWNE Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 | | | | | | | | | Estim | OMB Number: 3235-0287 Estimated average burden hours per response: 0.5 | | | | |
| 1. Name and Address of Reporting Person [*] Goddard Glenn | | | | | 2. Issuer Name and Ticker or Trading Symbol Intellia Therapeutics, Inc. [NTLA] | | | | | | | 5. Relationship of Reporting Perso (Check all applicable) Director Officer (give title | | | 10% Owner Other (specify | |
| | (F ELLIA TH STREET; S | (Middle) INC. | | 3. Date of Earliest Transaction (Month/Day/Year) 03/01/2022 | | | | | | | below) below) EVP, Chief Financial Officer | | | | | |
| (Street) CAMBRIDGE MA | | | 02139 | | l. If Am)3/03/2 | | Date o | f Original Filed (Month/Day/Year) | | | Line | ndividual or Joint/Group Filing (Check Applicable e) X Form filed by One Reporting Person Form filed by More than One Reporting Person | | | | |
| (City) (State) (Zip) | | | | | | | | | | | | | | | | |
| | | Та | able I - Non-D | erivat | ive S | ecurities | s Ac | | - | - | - | Owned | | | | |
| 1. Title of Security (Instr. 3) | | | Dat | 'ransacti e onth/Day | - | 2A. Deemed Execution Date, if any (Month/Day/Year) | | Code (Ins | on Dispose | 4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4 | | | | Form: | Direct I Indirect E str. 4) 0 | 7. Nature of Indirect Beneficial Ownership |
| | | | | | | | | Code V | Amount | (A) o (D) | r Price | Transactio | | | | Instr. 4) |
| | Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) | | | | | | | | | | | | | | | |
| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) | | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | | 6. Date Exercisable and Expiration Date (Month/Day/Year) | | of Securit Underlyin | d Amount ies g Derivative Instr. 3 and | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) | | 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) |
| | | | | Code | v | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | | (Instr. 4) | | | |
| Stock Option (right to buy) | \$79.85 | 03/01/2022 | | A | | 18,600 ⁽¹⁾ | | (2) | 02/28/2032 | Common Stock | 18,600(1) | \$0.00 | 18,600 ⁽¹⁾ | | D | |

Explanation of Responses:

1. The original Form 4 incorrectly reported the number of options granted as 12,720.

2. This option was granted on March 1, 2022 with respect to shares of Common Stock, with 33% vesting on January 1, 2023 and the remaining 67% vesting in 24 substantially equal monthly installments thereafter. Remarks:

/s/ James Basta, attorney-in-fact 03/04/2022

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.